Dilip Shanghvi

Dilip Shanghvi had said in February that the judgment was crucial for Sun Pharma's future course of action on this drug launch.

Checkpoint is a commercial-stage company that develops novel treatments for patients with solid tumor cancers, and the acquisition includes UNLOXCYT, an FDA-approved treatment for advanced skin cancer.

Analysts said despite Shanghvi’s exit, there are a slew of reasons to be bullish on Suzlon.

Shanghvi said that the company’s businesses are well-positioned, and it expects high-single-digit consolidated topline growth for FY24

The Sun Pharma founder says it for his children, Aalok and Vidhi, to decide if they want to be owner-managers, working managers or adopt a hands-off approach

Shanghvi will, however, continue to be associated with the company's board in his capacity as a non-executive director and chairman, it added.

Multi-year opportunity awaits Indian vaccine manufacturers such as DRL, Gland Pharma, Aurobindo Pharma and Cadila Pharma

The whistle-blower alleged that Sun Pharma and its subsidiary, Sun Pharmaceutical Laboratories, had diverted funds through Aditya Medisales, its sole distributor in India.

In 2015, Shanghvi bought 23 percent stake in Suzlon for Rs 18 billion, helping the company to return to profitability after it became India’s largest convertible-bond defaulter in 2012.

The Aditya Birla Group today said it has received licence from the Reserve Bank of India to start payments bank.

India's richie rich club has shrunk by 11 people since the demonetisation last November, while Mukesh Ambani remains the richest Indian with a net worth of USD 26 billion, a study showed today.

India Post Payments Bank (IPPB) today kicked off its operations by rolling out pilot services in Raipur and Ranchi.

"India Post has received payments bank licence. The service will be launched as per schedule," a Department of Posts official said.

The study, released by rights group Oxfam ahead of the World Economic Forum (WEF) annual meeting here attended by rich and powerful from across the world, showed that just 57 billionaires in India now have same wealth (USD 216 billion) as that of the bottom 70 percent population of the country.

Till now, GIC Re was the only Indian reinsurance company. It is entitled to the right of first refusal and also has the privilege of cessions which means a portion of risk is to be mandatorily ceded to it by an insurer.

Paytm today said it has received final approval of the Reserve Bank to formally launch its payments bank and it expects to start operations next month.

For investors, the Sun Pharma stock has long stood for a focus on growth, both through organic and inorganic routes. Is this lack of focus through unrelated investments the reason for its underperformance?

India‘s top pharma and media barons are lining up to have a fill of the country‘s oil blocks. Sun Pharma founder Dilip Shanghvi and media tycoon Subash Chandra are in the fray for the government‘s oil and gas blocks auction.

Sun Pharma has significant investment plans for its facility in Madhya Pradesh, the firm's Managing Director Dilip Shanghvi said on Saturday.

Similarly, Wipro's Azim Premji, the 4th richest Indian on the Forbes list, has a networth of USD 15 billion -- more than Mozambique's GDP of USD 14.7 billion.